Role of Rifampin against Staphylococcal Biofilm Infections
            <i>In Vitro</i>
            , in Animal Models, and in Orthopedic-Device-Related Infections

Zimmerli, Werner; Sendi, Parham

doi:10.1128/aac.01746-18

Cited by 168 publications

(126 citation statements)

References 99 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, the superior efficacy of these two antibiotics is not related to their mechanisms of action, as rifampicin inhibits RNA polymerase (Campbell et al, 2001) and dalbavancin interferes with bacterial cell wall synthesis (Chen et al, 2007). Although rifampicin has been used in clinical practice against staphylococcal biofilm-related infections for almost three decades (Zimmerli and Sendi, 2019), this antibiotic should be administered carefully because of the danger of rapid emergence of rifampicin-resistant bacteria (Raad et al, 2007;Zhou et al, 2012). Thus, dalbavancin emerges as a promising solution in the fight against device-related infections, confirming the promising results obtained in animal models (Darouiche and Mansouri, 2005;Baldoni et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds

et al. 2020

View full text Add to dashboard Cite

Microorganisms grown in biofilms are more resistant to antimicrobial treatment and immune system attacks compared to their planktonic forms. In fact, infections caused by biofilm-forming Staphylococcus aureus and Staphylococcus epidermidis are a large threat for public health, including patients with medical devices. The aim of the current manuscript was to test the effect of dalbavancin, a recently developed lipoglycopeptide antibiotic, alone or in combination with compounds contributing to bacterial cell disaggregation, on staphylococcal biofilm formation and elimination. We used realtime impedance measurements in microtiter plates to study biofilm growth dynamics of S. aureus and S. epidermidis strains, in the absence or presence of dalbavancin, linezolid, vancomycin, cloxacillin, and rifampicin. Further experiments were undertaken to check whether biofilm-detaching compounds such as N-acetylcysteine (NAC) and ficin could enhance dalbavancin efficiency. Real-time dose-response experiments showed that dalbavancin is a highly effective antimicrobial, preventing staphylococcal biofilm formation at low concentrations. Minimum biofilm inhibitory concentrations were up to 22 higher compared to standard E-test values. Dalbavancin was the only antimicrobial that could halt new biofilm formation on established biofilms compared to the other four antibiotics. The addition of NAC decreased dalbavancin efficacy while the combination of dalbavancin with ficin was more efficient than antibiotic alone in preventing growth once the biofilm was established. Results were confirmed by classical biofilm quantification methods such as crystal violet (CV) staining and viable colony counting. Thus, our data support the use of dalbavancin as a promising antimicrobial to treat biofilm-related infections. Our data also highlight that synergistic and antagonistic effects between antibiotics and biofilm-detaching compounds should be carefully tested in order to achieve an efficient treatment that could prevent both biofilm formation and disruption.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds

et al. 2020

View full text Add to dashboard Cite

show abstract

“…No significant side effects related to daptomycin were observed. Finally, the combination of daptomycin with rifampin, which has been linked to improved clearance of staphylococcal biofilm in multiple models of study 34 , should be the target of future formal clinical investigations to determine if a clinical effect on outcomes and prevention of emergence of resistance is observed.…”

Section: Discussionmentioning

confidence: 99%

Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection

Carli

Miller

Kapadia

et al. 2020

J. Bone Joint Infect.

View full text Add to dashboard Cite

Background: The role of daptomycin, a potent, safe, convenient anti-staphylococcal antibiotic, in treatment of prosthetic joint infection (PJI) is unclear. We evaluated our experience with the largest cohort of patients with staphylococcal PJI managed with daptomycin. Methods: A cohort of staphylococcal hip and knee PJI treated with daptomycin was identified by hospital records from 2009 to 2016. All cases met Musculoskeletal Infection Society International Consensus criteria for PJI. The primary endpoint was 2 year prosthesis retention. Univariate analyses and regression statistics were calculated. Results: 341 patients with staphylococcal PJI were analyzed. 154 two-stages (77%) and 74 DAIR procedures (52%) met criteria for treatment success at 2 years. 77 patients were treated with daptomycin, of which 34 two-stages (68%) and 15 DAIRs (56%) achieved treatment success. Pairwise and regression analysis found no association between treatment success and daptomycin use. Organism (DAIR only) and Charlson Comorbidity Index scores (DAIR and two-stage) were significantly associated with treatment outcome. Six daptomycin patients (7.8%) had adverse side effects. Discussion: Daptomycin fared no better or worse than comparable antibiotics in a retrospective cohort of staphylococcal hip and knee PJI patients, regardless of surgical strategy. Conclusion: The convenient dosing, safety, and potency of daptomycin make it an attractive antibiotic for staphylococcal PJI. However, these advantages must be weighed against higher costs and rare, but serious side effects.

show abstract

“…Radical debridement is the mainstay of treatment for all cases, but possible reasons for the improvement may be the modifications in surgical management and antimicrobial therapy that we have employed since then. We used systemic rifampicin in the majority (93.1 %) of cases for an average of 23.7 days [28]. Prior to the reimplantation of new components, the surgical field was also irrigated with a computed formulation of polyhexanide [29, 30].…”

Section: Discussionmentioning

confidence: 99%

Improved treatment strategies can result in better outcomes following one-stage exchange surgery for MRSA periprosthetic joint infection

Ohlmeier

Filitarin

Delgado

et al. 2020

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. Periprosthetic joint infections caused by methicillin-resistant Staphylococcus aureus (MRSA-PJIs) are rare, with only a few studies reporting the treatment outcomes and even fewer reporting outcomes with one-stage exchange. Aim. This study aims to analyse the outcomes of one-stage exchange in the management of MRSA-PJIs. Methodology. Patients with MRSA-PJI of the hip and knee, who were treated with a one-stage exchange between 2001 and 2018 were enrolled in this study. The final cohort comprised of 29 patients, which included 23 hips and six knees. The mean follow-up was 5.3 years (1–9 years). Reinfection and complications rates after the one-stage exchange were analysed. Results. Overall infection control could be achieved in 93.1 % (27 out of 29 patients). The overall revision rate was 31.0% (9 patients), with three patients requiring an in-hospital revision (10.3 %). Six patients had to be revised after hospital discharge (20.7 %). Of the two reinfections, one had a growth of MRSA while the other was of methicillin-sensitive Staphyloccocus epidermidis. Conclusion. One-stage exchange surgery using current techniques could improve surgical outcomes with excellent results in the management of MRSA-PJIs.

show abstract

Role of Rifampin against Staphylococcal Biofilm Infections In Vitro , in Animal Models, and in Orthopedic-Device-Related Infections

Cited by 168 publications

References 99 publications

Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds

Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds

Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection

Improved treatment strategies can result in better outcomes following one-stage exchange surgery for MRSA periprosthetic joint infection

Contact Info

Product

Resources

About